Marvel Biosciences Corp.
MRVL.V
TSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -31.35% | 25.94% | 35.51% | 44.59% | 29.02% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 168.14% | 1,083.84% | 595.37% | 416.15% | 249.58% |
| Change in Net Operating Assets | 52.94% | -84.66% | -72.66% | -107.19% | -79.19% |
| Cash from Operations | 4.94% | 12.57% | 20.04% | 2.42% | 12.70% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 1.88% | 185.00% | -66.67% | 0.00% | 0.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -180.25% | -- | -- | -- | -613.64% |
| Cash from Financing | -7.61% | 156.44% | -68.97% | -3.49% | -25.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.28% | 119.98% | -288.19% | -2.27% | -361.90% |